By D. Keldron. Purdue University North Central. 2018.
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month purchase albuterol 100mcg mastercard, open-label discount albuterol 100 mcg, observational discount albuterol 100 mcg with visa, primary care study. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Impact of oral antihyperglycemic therapy on all- cause mortality among patients with diabetes in the Veterans Health Administration. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Coronary heart disease outcomes in patients receiving antidiabetic agents. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile. Effects of pioglitazone and insulin on tight glycaemic control assessed by the continuous glucose monitoring system: A monocentric, parallel-cohort study. Thiazolidinediones Page 104 of 193 Final Report Update 1 Drug Effectiveness Review Project 188. Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: A practical approach for the primary care physician. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Orbay E, Sargin M, Sargin H, Gozu H, Bayramicli OU, Yayla A. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes. Osei K, Gaillard T, Kaplow J, Bullock M, Schuster D. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Thiazolidinediones Page 105 of 193 Final Report Update 1 Drug Effectiveness Review Project 203. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
METHODS Literature Search To identify articles relevant to each key question albuterol 100mcg amex, we originally searched (in this order): the Evidence-Based Medicine Library (2002 cheap albuterol 100 mcg amex, Issue 1) (from the Cochrane Collaboration) 100 mcg albuterol mastercard, MEDLINE (1966-2003), EMBASE (1980-2003), and reference lists of review articles. In electronic searches we combined terms for spasticity, conditions associated with spasticity, and musculoskeletal disorders with included skeletal muscle relaxants (see Appendix A for complete search strategy). In addition, a submission protocol was created and disseminated to pharmaceutical manufacturers for the submission of clinical and economic evaluation data to the Evidence-based Practice Center. All citations were imported into an electronic database (EndNote 6. Original searches on the electronic databases were carried out through January 2003, using updates on electronic databases after the initial searches. We conducted Update #3 searches of the Cochrane Library (through third quarter, 2004), MEDLINE (through November week 3 2004), and Embase (through third quarter, 2004) using the same search strategy as for the initial searches. Pharmaceutical manufacturers Skeletal Muscle Relaxants Page 8 of 237 Final Report Update 2 Drug Effectiveness Review Project were again invited to submit update dossiers, including citations. These submissions were reviewed to identify new citations not previously submitted. Study Selection All English-language titles and abstracts and suggested additional citations were reviewed for inclusion, using criteria developed by the research team with input from the subcommittee. We obtained full-text articles if the title and abstract review met the following criteria: 1. Systematic reviews of the clinical efficacy or adverse event rates of skeletal muscle relaxants for spasticity or musculoskeletal conditions OR 2. Randomized controlled trials that compared one of the included skeletal muscle relaxants listed to another included skeletal muscle relaxant, other antispasticity or muscle relaxant treatment (diazepam, gabapentin, clonidine, chlorazepate, or clonazepam), or placebo in adult patients with spasticity or musculoskeletal conditions OR 3. Randomized controlled trials and large, high quality observational studies that reported adverse event rates for one of the skeletal muscle relaxants listed above. We then applied the same criteria to the full-text articles, ensuring that the clinical efficacy or adverse event rates from specific skeletal muscle relaxants were reported or could be calculated. While we preferred studies of longer duration, we had no lower limit on the length of follow-up, but excluded “single-dose studies” examining the effects of a single dose of medication rather than a course of treatment. We also excluded trials in which an included skeletal muscle relaxant was combined with an analgesic medication unless the comparison arm included the same analgesic medication and dose. We excluded abstracts and unpublished trials unless the unpublished data was submitted by a pharmaceutical company, and included only English-language studies. Original searches identified 3,847 citations: 335 from the Evidence-Based Medicine (Cochrane) Library, 1,155 from MEDLINE, 2,314 from EMBASE, and 43 from reference lists. We identified 377 reports of clinical trials and excluded 227 of these (see Appendix B for detailed search results). Sixty-seven were excluded because they did not evaluate an included population, 148 were excluded because they did not evaluate an included intervention (skeletal muscle relaxant), seven were excluded because they did not evaluate an included outcome (spasms, pain, strength, functional ability, or adverse events), one was excluded because it was a single-dose study, and four were excluded because they were not English-language. We retrieved 150 reports on clinical trials for more detailed evaluation. After this second review, we excluded 52: 39 because they did not evaluate an included intervention, one because it did not evaluate an included population, one because it did not contain original data, two because they did not evaluate an included outcome, six because of study design (results published in another reviewed trial, not a controlled trial, or no data), and three because they were not English-language. Ninety-eight reports presenting data for 101 randomized controlled trials provided usable data and are included in evidence tables. We also identified four relevant systematic reviews and three 40-45 meta-analyses. Seven placebo-controlled trials (reported in six publications) were 46 subsequently identified and added while the report was prepared for journal submission. Skeletal Muscle Relaxants Page 9 of 237 Final Report Update 2 Drug Effectiveness Review Project 590 new citations were identified from Update #1 (October 2003) searches. Thirty trials were excluded for the following reasons: 8 did not evaluate an included patient population, 18 did not evaluate an included intervention, 1 was an abstract only, and 3 were non-English language. We also identified two separate reports of a single systematic review 48, 49 on muscle relaxants for acute low back pain. Pharmaceutical dossiers submitted for cyclobenzaprine (McNeil Consumer Pharmaceuticals) and metaxalone (King Pharmaceuticals) identified 2 citations not otherwise identified. The remaining 21 citations were identified from reference lists and hand searches. Of the new citations, 18 were reports of clinical trials of skeletal muscle relaxants. Five systematic reviews were also 59 identified during Update #2 searches that met inclusion criteria; one was an update of a 27 60-63 previously included systematic review and the remainder were newly published studies. Data Abstraction One reviewer abstracted the following data from included trials: study design, setting, population characteristics (including sex, age, race, diagnosis), eligibility and exclusion criteria, interventions (dose and duration), comparisons, numbers screened, eligible, enrolled, and lost to follow-up, method of outcome ascertainment (e. We recorded intention-to-treat results if available and the trial did not report high overall loss to follow-up. In trials with crossover, outcomes for the first intervention were recorded if available to minimize potential bias in results due to differential withdrawal prior to crossover. We also wanted to screen out the possibility of a “carryover” effect from the first treatment in studies without a washout period or “rebound” spasticity from withdrawal of the 64 first intervention. Quality Assessment We assessed quality of trials based on the predefined criteria listed in Appendix C. We rated the internal validity of each trial based on methods used for randomization; allocation concealment and blinding; the similarity of compared groups at baseline; maintenance of comparable groups; adequate reporting of dropouts, attrition, crossover, adherence, and contamination; loss to follow-up; and the use of intention-to-treat analysis. External validity of trials was assessed based on: adequate description of the study population; similarity of Skeletal Muscle Relaxants Page 10 of 237 Final Report Update 2 Drug Effectiveness Review Project patients to other populations to whom the intervention would be applied; control group receiving comparable treatment; funding source; and role of the funder. Overall quality was assigned based on criteria developed by the US Preventive Services 38, 39 Task Force and the National Health Service Centre for Reviews and Dissemination (UK). Trials with a fatal flaw in one or more categories were rated poor-quality. Trials that met all criteria were rated good-quality.
However albuterol 100 mcg, only patients randomized to both memantine and donepezil faired significantly better on the CIBIC-plus and NPI than patients randomized to placebo plus 60 donepezil order albuterol 100 mcg fast delivery. In the memantine monotherapy study discount albuterol 100mcg free shipping, no differences in MMSE, CIBIC-plus, GDS, or NPI were reported between memantine- and placebo-treated patients. One trial incorporated a resource utilization scale, 60 and the other trial used a behavioral rating scale (BGP) that assesses caregiver dependence. Both trials showed significantly greater improvement in caregiver burden (P < 0. Summary of the evidence Comparative evidence for drugs used to treat AD is limited to three open-label head-to-head efficacy 27, 28 29 trials; two trials compared donepezil to galantamine and one compared donepezil to rivastigmine. In one 52-week trial, donepezil and galantamine did not differ in stabilizing symptoms or improving behavior and functional status. In a 28 shorter trial (12 weeks), donepezil was superior to galantamine in its effects on cognition, functional status, and caregiver and clinician satisfaction. The comparison of donepezil to rivastigmine is limited to 29 a single 12-week trial; it produced similar improvement in cognitive scores for both drugs, although clinician and caregiver satisfaction ratings were significantly better for donepezil. Evidence from placebo-controlled trials and systematic reviews of placebo-controlled trials provide general evidence of the efficacy and effectiveness of these drugs. Overall, the ChEIs as a class are 30, 31 modestly effective in reducing the rate of decline in cognition. The NNT to yield one additional ChEI 30 (excluding tacrine) global responder is 12; the NNT to yield one additional cognitive responder is 10. Evidence from placebo-controlled trials and a systematic review of placebo-controlled trials provide general evidence of the efficacy of memantine. Although some trials did not support statistically significant differences between active treatment and 38, 39, 42, 45, 48-51, 54, 58, 59 placebo on all outcome measures, most trials yielded data supporting a slower rate of decline or modest improvement in measures of cognition and global assessment. Fewer trials supported differences in measures of behavior or functioning. Caregiver burden was infrequently assessed or reported, although 4 trials found significantly greater improvement for active treatment compared to 52, 59, 60, 64, 65 placebo. Only one study assessed nursing home placement as a function of medication 38 treatment. This trial did not detect significant differences in institutionisations between donepezil and placebo after 1 and 3 years. The clinical significance of some statistical differences is controversial. Although some trials defined clinical and global responders a priori, inconsistencies in trial design and reporting make it difficult to assess the clinical relevance of differences across trials. Overall, the quality of evidence of general efficacy of ChEIs and memantine is fair; the quality of 38 evidence of effectiveness of ChEIs and memantine is limited to one study on donepezil and therefore poor. On the basis of current evidence, we cannot demonstrate substantial differences in efficacy between one AD drug and another. Placebo 32 Birks, 2004 (MA) NR 436 > 12 Mild – Symptoms: significantly better cognitive Good 5 moderate and global assessment scores for DON Behavior / function: no differences in QoL and functional capacity Whitehead et al. Placebo Loy & Schneider, NR 3,77 >4 NR Symptoms: significantly slower decline in Good 34, 62 2005 (SR) 7 cognitive and global assessment scores for GAL 16-32mg/d Behavior / function: Mixed evidence for behavior and function; most trials reported statistically significant differences only at higher doses Brodaty et al. We did not identify any study that directly compared the time to effect or time required to assess the clinical response of one AD drug compared to another. One open-label head-to-head trial provides 28 evidence on the time to effect between donepezil and galantamine. The study reports a trend favoring 28 donepezil in cognition at weeks 4 and 8 that reached statistical significance at week 12 (P < 0. DAD scores were significantly greater in donepezil-treated patients at weeks 4 and 12. Other head-to-head trials reported only long-term outcomes. Placebo-controlled trials are too heterogeneous with respect to study design, outcomes assessment, and populations to allow any inferences about the comparative time to effect. Given that the overall placebo- controlled evidence indicates that long-term treatment with ChEIs and memantine will produce only modest beneficial effects on cognition and global assessment, the clinical significance of time to effect is likely to be of minimal importance to physicians and patients. In general determining time to effect and time required to assess clinical response is difficult, given the design of most trials and the nature of measurement scales. First, trials commonly were not designed to measure the time required to produce a statistically different response. In most trials, the first follow-up visit was not conducted until 4 to 12 weeks after randomization. Given this relatively large and inconsistent gap in follow-up between randomization and first clinical assessment, comparison across placebo-controlled trials cannot provide accurate information. Second, different studies used different outcome scales that are not necessarily comparable to assess effect sizes. Third, the ability of a trial to detect statistically significant difference depends on the sample size of each respective trial; trials with large sample sizes have greater power to present statistically significant findings at earlier time points. Interpretation of clinical response (and time to assess it) is also of concern. Three published studies have 51, 78, 79 78 sought to shed light on the clinical significance of treatment effects in AD trials. In one the authors calculated standardized effect sizes from ChEI trials to assess clinically detectable responses.
In patients with acute coronary syndrome a dual antiplatelet therapy should be maintained for at least 12 months discount albuterol 100 mcg on-line. The indication for invasive vascular diagnostic and intervention depends on current guidelines (http://www buy albuterol 100mcg lowest price. Clear indications for coronary angiography are a documented exercise-induced ischemia albuterol 100 mcg lowest price, typical clinical symptoms together with ST alterations in the ECG, increases in cardiac enzymes and/or a marked cardiovascular risk profile. It is worth emphasizing that HIV infec- tion is not an exclusion criteria for invasive procedures. Successful coronary inter- ventions have been performed on HIV+ patients, including catheter procedures with implantation of drug-eluting stents (DES) (Saporito 2005, Glazier 2006, Neumann 2010) and coronary artery bypass operations (Filsoufi 2006). However, there are some reports that show an increased rate of re-stenosis after DES and increased rate of “major adverse cardiac events” following surgical revascularization in HIV+ patients (Boccara 2008, Ren 2009). Recommendations for follow-up HIV+ patients with cardiovascular risk factors should undergo an annual cardiac check-up, including a resting ECG and estimation of the cardiovascular disease risk based on the available risk scores. Symptomatic patients need further cardiovascu- lar examinations (exercise ECG, stress echocardiography, laboratory work-up and, in some cases, myocardial scintigraphy or coronary angiography). In HIV+ patients, HIV-associated dilated cardiomyopathy is of major interest. It corresponds to a reduced systolic function with a dilated and less contractile left ventricle (Dakin 2006, Butt 2012). Myocarditis is still the most thoroughly studied cause of conges- tive heart failure in HIV disease. Until now, a variety of pathogens has been found in the myocardial tissue of HIV+ patients (Patel 1996, Wu 1992). Furthermore, HIV itself appears to infect myocardial cells in a patchy distribution. Myocardial damage by gp120 and cytokine-mediated apoptosis is presumed (Fiala 2004). Especially, HIV- 1 is known to cause cardiomyopathy (Lopes de Campos 2014). In addition to a direct impact of HIV or other pathogens, dilated cardiomyopathy was reported in associ- ation with an autoimmune reaction. Cardiac-specific autoantibodies (anti- -myosin antibodies) have been reported in up to 30% of HIV+ patients with cardiomyopa- thy. However, several studies indicate that dilated cardiomyopathy is associated with cardiotoxic agents (e. Furthermore, it is under discussion whether antiretro- viral drugs may induce cardiac dysfunction due to mitochondrial toxicity (Lewis 2006, Purevjav 2007). A retrospective study of a large cohort showed an association of tenofovir intake and incident heart failure (Choi 2011). The prevalence of congestive heart failure in the pre-ART era was between 9% and 52% (Ntsehke 2005) and 29% in patients with AIDS (Levy 1989). Since the intro- duction of ART the prevalence of dilated cardiomyopathy seems to have decreased. In a recent register study the rate of death due to cardiomyopathy was higher than in negative controls. However, the rate of death due to heart failure was lower (Whiteside 2015). In recent years, growing evidence has been found that not only systolic function can be impaired in HIV+ patients but also diastolic function. However, impairment of diastolic function was often asymptomatic. There is uncertainty about the causes for diastolic impairment, although there is evidence that it seems to be mainly related to HIV infection itself rather than to ART (Fontes-Carvalho 2015). Chronic heart failure is associated with a reduced life expectancy. In cases of NYHA III-IV, the annual mortality rate rises to 25%. While in some cases a total recovery has been described (Fingerhood 2001, Tayal 2001), the majority of patients with HIV- associated dilated cardiomyopathy have a progression of left ventricular dysfunction and a poor prognosis (Felker 2000). It is unclear whether ART has an influence on the recovery of ventricular function. Potentially helpful for the assessment of prognosis in HIV cardiomyopathy is the evaluation of contractile reserve by stress echocardiography (Wever-Pinzon 2011). Early diagnosis and conventional therapy seem to be the most promising ways to reduce disease progression. Unfortunately, heart failure is often not recognized. In a prospective study of 416 HIV+ patients with unknown heart disease the frequency of cardiac dysfunction was 17. Diastolic dysfunction was found in up to 48% of subjects in the HIV-HEART study (Reinsch 2010). Besides left ventricular dysfunc- tion, cardiomyopathy often includes dilatation and reduced contraction of the right ventricle. However, a Danish study that enrolled 90 HIV+ patients did not find an increased rate of right ventricular dysfunction (Kjaer 2006). The diagnosis of chronic heart failure is based on clinical findings and symptoms. In addition to exercise intolerance, patients often exhibit dyspnea and edema. Nocturia, night cough (cardiac asthma), peripheral cyanosis and weight increase may HIV and Cardiac Diseases 591 also occur.
10 of 10 - Review by D. Keldron
Votes: 107 votes
Total customer reviews: 107